This activity has been planned and implemented by the Duke University Health System Department of Clinical Education and Professional Development and Med-IQ.
One in eight patients with non-Hodgkin lymphoma has this indolent subtype.
One in eight patients with non-Hodgkin lymphoma has follicular lymphoma. (Teras LR, et al. CA Cancer J Clin. 2016. [Epub ahead of print.])
Activity Medical Director
Linda M. Sutton, MD
Associate Chief Medical Officer, Duke Network Services
Medical Director, Duke Cancer Network
Associate Professor of Medicine
Division of Medical Oncology
Duke University School of Medicine
David A. Rizzieri, MD
Professor of Medicine
Chief, Section of Hematologic Malignancies
Associate Director for Clinical Research, Division of Hematologic Malignancies and Cellular Therapy
Department of Medicine
Duke University School of Medicine
Kerri A. Dalton, MSN, RN, AOCNS
Director, Clinical Practice & Education
Duke Cancer Network, Network Services
Duke University Health System
Erin Grothey, MS
Clinical Content Manager
Laura Rafferty, ELS
Lori K. Pender, PharmD, MPH, ELS
Upon completion, participants should be able to:
- Outline the patient-, treatment-, and disease-specific factors important in selecting optimal therapy for patients with FL or DLBCL
- Incorporate key principles of shared decision making to engage patients with FL and DLBCL in the treatment planning process
This activity is designed for hematologist/oncologists, nurses, and pharmacists.
Statement of Need
The management of non-Hodgkin lymphoma (NHL) has been transformed in recent years with the approval of novel agents that have demonstrated significant survival gains across many subgroups of this heterogeneous patient population. Shared decision making between the oncology care team and patients is a critical element of patient-centered, high-quality cancer care, especially in light of the current role of individualized medicine in reaching optimal outcomes. However, many hematology/oncology clinical care teams are unsure of how to best incorporate shared decision making into routine practice, and others believe that patients want to be less involved in treatment decisions. With the expansion of available NHL treatments and continual escalation in the complexity of care, patient preferences are a critical element of the treatment-planning process. Thus, hematologist/oncologists, nurses, and pharmacists involved in the care of patients with NHL can benefit from education on integrating shared decision making into high-quality, evidence-based care.
Joint Accreditation Statement
This activity has been planned and implemented by the Duke University Health System Department of Clinical Education and Professional Development and Med-IQ for the advancement of patient care. The Duke University Health System Department of Clinical Education & Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the health care team.
In support of improving patient care, Duke University Health System Department of Clinical Education and Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team.
Category 1*: Duke University Health System Department of Clinical Education and Professional Development designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Nursing CE: Duke University Health System Department of Clinical Education and Professional Development designates this activity for up to 0.5 credit hours for nurses. Nurses should claim only credit commensurate with the extent of their participation in this activity.
Pharmacists: Duke University Health System Department of Clinical Education and Professional Development designates this activity for a maximum of 0.5 ACPE credit hours. Universal Activity Numbers: JA0000655-9999-18-071-H01-P
Medium/Method of Participation
This CE activity consists of a 0.5-credit online publication. To receive credit, read the introductory CE material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 80% of the post-test questions correctly.
Initial Release Date: May 24, 2018
Expiration Date: May 23, 2019
Estimated Time to Complete This Activity: 30 minutes
In order to successfully complete this activity for AMA PRA Category 1 Credit(s)™, learners must demonstrate performance by achieving a minimum of 80% on the post-test.
It is the policy of the Duke University Health System Clinical Education and Professional Development to require the disclosure of anyone who is in a position to control the content of an educational activity. All relevant financial relationships with any commercial interests and/or manufacturers must be disclosed to participants at the beginning of each activity.
Duke University Health System Clinical Education and Professional Development has implemented a process to resolve any potential conflicts of interest for each continuing education activity in order to help ensure content objectivity, independence, fair balance, and the content that is aligned with the interest of the public.
The following speakers and/or planning committee members have indicated they have no relationship(s) with industry to disclose relative to the content of this CE activity: Kerri A. Dalton, MSN, RN, AOCNS, Erin Grothey, MS, Lori K. Pender, PharmD, MPH, ELS, Laura Rafferty, ELS, and Linda M. Sutton, MD
The following speakers and/or planning committee members have indicated that they have relationship(s) with industry to disclose:
David A. Rizzieri, MD
Consulting fees/advisory boards: Celgene Corporation, Gilead Sciences, Inc., Incyte Corporation, Sanofi-aventis U.S. Inc., Spectrum Pharmaceuticals, Teva Pharmaceuticals Industries Ltd.
Other (speaker): Celgene Corporation, Gilead Sciences, Inc., Incyte Corporation, Spectrum Pharmaceuticals, Teva Pharmaceuticals Industries Ltd.
The writer, peer reviewers, and activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
For questions or comments about this activity, please contact Med-IQ.
Call (toll-free) 866 858 7434 or email firstname.lastname@example.org.
For CE related questions or comments about this activity, please contact Duke Health. Kerri Dalton at email@example.com or via phone at 919-613-1391
Microsoft Windows® 8, Windows 7
Mac OS 10.7 (Lion) or newer
Microsoft Internet Explorer 8.0 or later
Mozilla Firefox - latest version
Google Chrome - latest version
Apple Safari - latest version
Adobe Acrobat Reader® or Adobe Reader
Adobe Flash Player
Adobe Flash Player 9 or later
For technical support, go to http://www.med-iq.com/index.cfm?fuseaction=content.support.
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Privacy & Confidentiality
Acknowledgment of Commercial Support
This CE activity is supported by an educational grant from Genentech.
© 2018 Duke University Health System and Med-IQ, Inc.
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.